...no treatment. Next steps could include optimizing the vaccine to improve potency. Immutep Ltd. and Neopharm...

...B cell non-Hodgkin’s lymphoma (NHL) in patients who have received <=3 prior courses of treatment. Neopharm...

...The product has Orphan Drug designation in the U.S. and EU. In February, Prima granted Neopharm...

...Prima granted Neopharm an exclusive license to market Prima's CVac in Israel and the Palestinian Authority...
...the deal. Prima will receive a "small" upfront payment and is eligible for development milestones. Neopharm...
...CD227 ) and a mannan-fusion protein (M-FP). The companies declined to disclose financial details. Neopharm...

...Europe and Mexico. Otsuka Pharmaceutical Co. Ltd. (Tokyo, Japan) has exclusive rights in the U.S. Neopharm...

...Research S.A.S. (Rennes, France) in December 2012 and sold its Analytical Services division to its NeoPharm...

...rights in the rest of Europe and Mexico. Otsuka has exclusive rights in the U.S. Neopharm...

...Prima entered into a binding term sheet to grant Neopharm an exclusive license to market Prima's...
...term sheet. Prima will receive a "small" upfront payment and is eligible for development milestones. Neopharm...
...product has Orphan Drug designation in the U.S. and EU (see BioCentury, June 6, 2011). Neopharm...

...rights in the rest of Europe and Mexico. Otsuka has exclusive rights in the U.S. Neopharm...

...payments covering their wages and salaries up until the end of the year. In July, Neopharm...